Crossmark

STIM1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemia

Crossref DOI link: https://doi.org/10.1186/s40425-019-0591-3

Published Online: 2019-04-23

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Debant, Marjolaine

Burgos, Miguel

Hemon, Patrice

Buscaglia, Paul

Fali, Tinhinane

Melayah, Sarra

Le Goux, Nelig

Vandier, Christophe

Potier-Cartereau, Marie

Pers, Jacques-Olivier

Tempescul, Adrian

Berthou, Christian

Bagacean, Cristina

Mignen, Olivier

Renaudineau, Yves https://orcid.org/0000-0001-5098-5002
Funding

Funding for this research was provided by:

Ligue Contre le Cancer
License Information

Text and Data Mining valid from 2019-04-23
More Information

Article History

Received: 30 January 2019

Accepted: 2 April 2019

First Online: 23 April 2019

Ethics approval and consent to participate

: This study was approved by the Ethical Board at the Brest University Hospital (OFICE, November 26th, 2015; clinicaltrials: NCT03294980) in accordance with the declaration of Helsinki.

: Written informed consent was obtained from all of the patients.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.